028300.KQ
HLB Co., Ltd. [028300.KQ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
028300.KQ Stock Summary
Top 10 Correlated ETFs
028300.KQ
Top 10 Correlated Stocks
028300.KQ
In the News
028300.KQ Financial details
Company Rating
Sell
Market Cap
12142.95B
Income
-189.08B
Revenue
42.9B
Book val./share
4033.79
Cash/share
868.56
Dividend
-
Dividend %
-
Employees
133
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-49.38
Forward P/E
-
PEG
-4.42
P/S
76.31
P/B
9.24
P/C
112.83
P/FCF
-74.13
Quick Ratio
1.55
Current Ratio
1.65
Debt / Equity
0.09
LT Debt / Equity
0.03
-
-
EPS (TTM)
-1.47K
EPS next Y
-
EPS next Q
-
EPS this Y
124.66%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
28.9%
Revenue last 5Y
2.23%
Revenue Q/Q
-7.28%
EPS Q/Q
458.18%
-
-
-
-
SMA20
-8.95%
SMA50
41.61%
SMA100
206.27%
Inst Own
-
Inst Trans
-
ROA
-13%
ROE
-20%
ROC
-0.15%
Gross Margin
18%
Oper. Margin
-145%
Profit Margin
-146%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
27550.0-129000.0
52W High
-24.03%
52W Low
+255.72%
RSI
52.72
Rel Volume
0.37
Avg Volume
3.8M
Volume
1.42M
Perf Week
6.52%
Perf Month
22.65%
Perf Quarter
238.51%
Perf Half Y
218.7%
-
-
-
-
Beta
0.481
-
-
Volatility
2777.17%, 8078.69%
Prev Close
0.72%
Price
98000
Change
5.49%
028300.KQ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 379.35 | 454.22 | 581.02 | 1.6K | 353.86 | |
| Net income per share | -438.25 | -647.59 | -816.5 | -694.2 | -1.56K | |
| Operating cash flow per share | -480.41 | -456.94 | -455.7 | -549.04 | -920.78 | |
| Free cash flow per share | -498.99 | -1.06K | -506.8 | -661.2 | -979.01 | |
| Cash per share | 512.99 | 1.81K | 1.06K | 1.81K | 930.45 | |
| Book value per share | 1.83K | 3.88K | 3.63K | 5.67K | 4.32K | |
| Tangible book value per share | 549.81 | 2.37K | 1.44K | 3.15K | 4.49K | |
| Share holders equity per share | 1.83K | 3.88K | 3.63K | 5.67K | 4.32K | |
| Interest debt per share | 1.06K | 416.64 | 611.11 | 1.14K | 402.53 | |
| Market cap | 4830.18B | 5223.25B | 3818.91B | 2991.64B | 6449.72B | |
| Enterprise value | 4877.95B | 5057.57B | 3798.66B | 2925.79B | 6403.54B | |
| P/E ratio | -108.82 | -65.21 | -38.92 | -38.28 | -34.11 | |
| Price to sales ratio | 125.72 | 92.98 | 54.69 | 16.65 | 150.34 | |
| POCF ratio | -99.27 | -92.42 | -69.73 | -48.4 | -57.78 | |
| PFCF ratio | -95.57 | -39.72 | -62.7 | -40.19 | -54.34 | |
| P/B Ratio | 26.12 | 10.89 | 8.76 | 4.69 | 12.31 | |
| PTB ratio | 26.12 | 10.89 | 8.76 | 4.69 | 12.31 | |
| EV to sales | 126.96 | 90.03 | 54.4 | 16.28 | 149.26 | |
| Enterprise value over EBITDA | -106.17 | -62.54 | -43.26 | -50.15 | -58.73 | |
| EV to operating cash flow | -100.25 | -89.49 | -69.36 | -47.33 | -57.36 | |
| EV to free cash flow | -96.52 | -38.46 | -62.37 | -39.3 | -53.95 | |
| Earnings yield | -0.01 | -0.02 | -0.03 | -0.03 | -0.03 | |
| Free cash flow yield | -0.01 | -0.03 | -0.02 | -0.02 | -0.02 | |
| Debt to equity | 0.47 | 0.1 | 0.16 | 0.18 | 0.09 | |
| Debt to assets | 0.24 | 0.07 | 0.09 | 0.12 | 0.06 | |
| Net debt to EBITDA | -1.04 | 2.05 | 0.23 | 1.13 | 0.42 | |
| Current ratio | 1.03 | 2.57 | 1.54 | 1.71 | 1.67 | |
| Interest coverage | -2.46 | -17.35 | -27.52 | -6.39 | 0 | |
| Income quality | 1.1 | 0.71 | 0.56 | 0.79 | 0.59 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | -0.01 | |
| Sales general and administrative to revenue | 0 | 0.01 | 0.01 | 0.01 | 0 | |
| Research and developement to revenue | 0.88 | 0.4 | 0.69 | 0.24 | 1.15 | |
| Intangibles to total assets | 0.37 | 0.37 | 0.46 | 0.36 | 0.05 | |
| Capex to operating cash flow | 0.04 | 1.33 | 0.11 | 0.2 | 0.06 | |
| Capex to revenue | -0.05 | -1.33 | -0.09 | -0.07 | -0.16 | |
| Capex to depreciation | -0.89 | -7.18 | -0.51 | -0.77 | -1.01 | |
| Stock based compensation to revenue | 0.02 | 0.12 | 0.1 | 0.02 | 0 | |
| Graham number | 4.24K | 7.52K | 8.16K | 9.41K | 12.31K | |
| ROIC | -0.18 | -0.16 | -0.2 | -0.11 | -0.19 | |
| Return on tangible assets | -0.19 | -0.18 | -0.24 | -0.13 | -0.26 | |
| Graham Net | -1.1K | 717.29 | -540.7 | 301.78 | -332.3 | |
| Working capital | 1.98B | 153.55B | 66.32B | 143.24B | 58.07B | |
| Tangible asset value | 55.69B | 293.65B | 172.84B | 354.2B | 544.42B | |
| Net current asset value | -103.69B | 102.52B | -43.37B | 75.33B | -25.07B | |
| Invested capital | 0.47 | 0.1 | 0.16 | 0.18 | 0.09 | |
| Average receivables | 8.23B | 12.22B | 28.94B | 83.01B | 68.45B | |
| Average payables | 1.43B | 2.13B | 4.18B | 4.4B | 5.36B | |
| Average inventory | 4.39B | 4.9B | 9.34B | 13.08B | 11.88B | |
| Days sales outstanding | 94.13 | 94.45 | 226.55 | 249.16 | 121.08 | |
| Days payables outstanding | 10.16 | 21.63 | 31.15 | 10.57 | 52.17 | |
| Days of inventory on hand | 50.61 | 32.23 | 84.63 | 35.08 | 85.23 | |
| Receivables turnover | 3.88 | 3.86 | 1.61 | 1.46 | 3.01 | |
| Payables turnover | 35.93 | 16.87 | 11.72 | 34.52 | 7 | |
| Inventory turnover | 7.21 | 11.32 | 4.31 | 10.41 | 4.28 | |
| ROE | -0.24 | -0.17 | -0.23 | -0.12 | -0.36 | |
| Capex per share | -18.58 | -606.26 | -51.1 | -112.15 | -58.22 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 286.02 | 161.21 | 33.86 | 75.83 | 69.46 | |
| Net income per share | -324.24 | -161.9 | -228.57 | -164 | -915.42 | |
| Operating cash flow per share | -104.21 | -144.72 | -148.8 | -375.66 | -204.82 | |
| Free cash flow per share | -109.43 | -194.86 | -129.22 | -386.67 | -220.13 | |
| Cash per share | 1.8K | 2.07K | 1.7K | 1.13K | 868.56 | |
| Book value per share | 5.63K | 5.34K | 4.92K | 4.78K | 4.03K | |
| Tangible book value per share | 3.13K | 2.99K | 2.63K | 2.46K | 4.19K | |
| Share holders equity per share | 5.63K | 5.34K | 4.92K | 4.78K | 4.03K | |
| Interest debt per share | 1.06K | 832.02 | 671.6 | 699.27 | 375.75 | |
| Market cap | 3011.26B | 4068.49B | 3959.93B | 3849.53B | 6909.31B | |
| Enterprise value | 2945.41B | 3936.11B | 3844.36B | 3809.12B | 6863.13B | |
| P/E ratio | -20.49 | -51.1 | -33.85 | -45.73 | -14.53 | |
| Price to sales ratio | 92.9 | 205.3 | 914.09 | 395.65 | 765.91 | |
| POCF ratio | -254.99 | -228.68 | -208.02 | -79.86 | -259.74 | |
| PFCF ratio | -242.82 | -169.84 | -239.54 | -77.59 | -241.68 | |
| P/B Ratio | 4.72 | 6.2 | 6.29 | 6.28 | 13.19 | |
| PTB ratio | 4.72 | 6.2 | 6.29 | 6.28 | 13.19 | |
| EV to sales | 90.87 | 198.62 | 887.41 | 391.49 | 760.79 | |
| Enterprise value over EBITDA | -213.47 | -155.12 | -123.51 | -140.91 | -301.24 | |
| EV to operating cash flow | -249.41 | -221.24 | -201.95 | -79.02 | -258 | |
| EV to free cash flow | -237.51 | -164.32 | -232.55 | -76.77 | -240.06 | |
| Earnings yield | -0.01 | 0 | -0.01 | -0.01 | -0.02 | |
| Free cash flow yield | 0 | -0.01 | 0 | -0.01 | 0 | |
| Debt to equity | 0.18 | 0.15 | 0.13 | 0.14 | 0.09 | |
| Debt to assets | 0.12 | 0.1 | 0.09 | 0.1 | 0.06 | |
| Net debt to EBITDA | 4.77 | 5.22 | 3.71 | 1.49 | 2.03 | |
| Current ratio | 1.71 | 1.79 | 1.65 | 1.5 | 1.67 | |
| Interest coverage | -4.84 | -4.52 | -5.85 | -4.43 | 0 | |
| Income quality | 0.32 | 0.89 | 0.65 | 2.29 | 0.22 | |
| Dividend Yield | 0.08 | 0 | 0 | 0 | 0 | |
| Payout ratio | -6.43 | 0 | -0.36 | 0 | 0 | |
| Sales general and administrative to revenue | 0.01 | 0.02 | 0.07 | 0 | 0 | |
| Research and developement to revenue | 0.22 | 0.34 | 1.78 | 0.18 | 3.65 | |
| Intangibles to total assets | 0.36 | 0.37 | 0.38 | 0.41 | 0.05 | |
| Capex to operating cash flow | 0.05 | 0.35 | -0.13 | 0.03 | 0.07 | |
| Capex to revenue | -0.02 | -0.31 | 0.58 | -0.15 | -0.22 | |
| Capex to depreciation | -0.14 | -2.54 | 1.05 | -0.58 | -0.81 | |
| Stock based compensation to revenue | -0.05 | 0.05 | 0.14 | 0 | 0 | |
| Graham number | 6.41K | 4.41K | 5.03K | 4.2K | 9.12K | |
| ROIC | -0.02 | -0.03 | -0.05 | -0.04 | -0.04 | |
| Return on tangible assets | -0.06 | -0.03 | -0.05 | -0.04 | -0.17 | |
| Graham Net | 299.82 | 225.84 | -16.43 | -343.62 | -310.2 | |
| Working capital | 143.24B | 123.33B | 93.05B | 55.31B | 58.07B | |
| Tangible asset value | 354.2B | 367.85B | 336.85B | 315.07B | 544.42B | |
| Net current asset value | 75.33B | 38.16B | 6.6B | -33.09B | -25.07B | |
| Invested capital | 0.18 | 0.15 | 0.13 | 0.14 | 0.09 | |
| Average receivables | 76.44B | 68.34B | 10.11B | 7.77B | 11.78B | |
| Average payables | 3.47B | 2.87B | 1.78B | 1.29B | 4.02B | |
| Average inventory | 13.1B | 10.17B | 8.35B | 7.86B | 9.21B | |
| Days sales outstanding | 340.62 | 63.57 | 129.1 | 86.2 | 141.98 | |
| Days payables outstanding | 12.86 | 9.44 | 13.96 | 8.55 | 57.77 | |
| Days of inventory on hand | 42.67 | 37.53 | 78.79 | 57.48 | 94.38 | |
| Receivables turnover | 0.26 | 1.42 | 0.7 | 1.04 | 0.63 | |
| Payables turnover | 7 | 9.53 | 6.45 | 10.53 | 1.56 | |
| Inventory turnover | 2.11 | 2.4 | 1.14 | 1.57 | 0.95 | |
| ROE | -0.06 | -0.03 | -0.05 | -0.03 | -0.23 | |
| Capex per share | -5.22 | -50.13 | 19.58 | -11.01 | -15.31 |
028300.KQ Frequently Asked Questions
What is HLB Co., Ltd. stock symbol ?
HLB Co., Ltd. is a KR stock and trading under the symbol 028300.KQ
What is HLB Co., Ltd. stock quote today ?
HLB Co., Ltd. stock price is $98000 today.
Is HLB Co., Ltd. stock public?
Yes, HLB Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 3.8M
- Market Capitalization 12142.95B
- Employee 133
- CEO Mr. Jung-Min Park
- Headquarters Ulsan,KR
- IPO Date 2008-12-24
-
Website
https://www.hlbkorea.com 
HLB Co., Ltd. manufactures pharmaceutical products, and builds ships. It manufactures and sells various types of lifeboats for marine plants, drill ships, and cruise vessels in South Korea. The company offers conventional type lifeboats, free fall type lifeboats, and rescue boats. It also provides marine and yacht engines; hooks; RIB, patrol, fishing, aluminum, and leisure boats; fishery inspection ships; and safety goods, as well as lifeboat and davit inspection and repair services, service engineering training, and spare parts for lifeboats and davits. In addition, the company develops Riboseranib, a targeted anti-cancer agent; and Apilia that is used for the treatment for ovarian cancer. HLB Co., Ltd. was founded in 1975 and is headquartered in Ulsan, South Korea.
